Boston Financial Mangement LLC Invests $225,000 in Natera, Inc. (NASDAQ:NTRA)

Boston Financial Mangement LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 1,420 shares of the medical research company’s stock, valued at approximately $225,000.

A number of other large investors have also added to or reduced their stakes in NTRA. Wellington Management Group LLP grew its holdings in Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after purchasing an additional 1,883,481 shares in the last quarter. PointState Capital LP grew its holdings in Natera by 112.0% during the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock valued at $99,343,000 after purchasing an additional 413,468 shares in the last quarter. Franklin Resources Inc. grew its holdings in Natera by 42.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock valued at $144,958,000 after purchasing an additional 328,375 shares in the last quarter. ARK Investment Management LLC grew its holdings in Natera by 65.6% during the 3rd quarter. ARK Investment Management LLC now owns 687,703 shares of the medical research company’s stock valued at $87,304,000 after purchasing an additional 272,361 shares in the last quarter. Finally, Maverick Capital Ltd. grew its holdings in Natera by 25.2% during the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after purchasing an additional 269,706 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Down 2.6 %

NTRA stock opened at $168.19 on Friday. The stock has a market cap of $22.20 billion, a PE ratio of -95.56 and a beta of 1.66. The firm’s 50-day simple moving average is $168.06 and its 200 day simple moving average is $144.78. Natera, Inc. has a fifty-two week low of $69.14 and a fifty-two week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Wall Street Analyst Weigh In

Several research analysts have weighed in on NTRA shares. Barclays initiated coverage on shares of Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price objective for the company. Morgan Stanley lifted their price target on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. increased their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Finally, Robert W. Baird boosted their price target on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $170.94.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 663 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 1,442 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $161.87, for a total value of $233,416.54. Following the transaction, the chief financial officer now directly owns 108,032 shares in the company, valued at $17,487,139.84. This trade represents a 1.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 295,772 shares of company stock worth $49,741,699. Insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.